- [Resource Hub](/) - [Resource](/?resource-type=product-documentation#library) - CyteFinder II HT # CyteFinder II HT Imaging System CyteFinder II HT is a high-throughput imaging system that scans up to 80 slides hands-free and uses machine learning to detect rare cells and find tissue without an operator. CyteFinder II HT comes out of RareCyte's rare-cell work — the detection approach behind circulating-tumor-cell (CTC) analysis — now in a walk-up, barcode-tracked scanner. Seven fluorescence channels handle immunofluorescence, while brightfield handles H&E and IHC on tissue-capable configurations, keeping cellular and tissue-based multiplexed analysis on one instrument. Scanning is designed to run unattended: a five-position automated turret and image-based autofocus work through the 81-slide tray on their own, while a machine-learning step flags rare cells and locates tissue as images come off the camera. Results are reviewable at the bench or from a remote workstation. CyteFinder II HT is for Research Use Only. It is not for use in diagnostic procedures. Read or download to see: - Up to 80 slides scanned hands-free. The tray holds 81 standard microscope slides (80 loaded automatically, one manual) at ±5.0 µm load repeatability, and a 1D/2D barcode workflow tracks each sample through the run. - A typical 20x whole-slide scan in about 6.5 minutes. Scanning a 1.5 cm × 1.5 cm area across five channels at 20 ms exposures takes roughly 6.5 minutes, autofocus included. - Seven fluorescence channels, from DAPI to the near-infrared. A five-color solid-state LED source drives seven fluorescence channels spanning DAPI to Qdot 800, with brightfield imaging for H&E and IHC on tissue configurations. - Machine-learning rare-cell detection on an sCMOS camera. A 2560 × 2160 sCMOS sensor with 6.5 µm pixels and 1.2 electrons of read noise feeds the rare-cell analysis and tissue-viewing software, with optional remote review. [Download spec sheet](https://cdn.sanity.io/files/s3p6uqps/production/cd9c7c7369ac85877997668a4988e4519de79cea.pdf) Your browser doesn't support embedded PDFs. [Download the CyteFinder II HT spec sheet](https://cdn.sanity.io/files/s3p6uqps/production/cd9c7c7369ac85877997668a4988e4519de79cea.pdf) to view it. [Back to all resources](/#library) ## Related resources [Article](https://www.selectscience.net/product-news/measuring-versus-reading-transforming-the-field-of-quantitative-pathology?artid=58733) CyteFinder SelectScience ### Measuring versus reading – transforming the field of quantitative pathology [Read Article](https://www.selectscience.net/product-news/measuring-versus-reading-transforming-the-field-of-quantitative-pathology?artid=58733) [Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyz2/455452/220143/TS20_104.pdf) CyteFinder ### CyteFinder II [View Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyz2/455452/220143/TS20_104.pdf) [Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026 ### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes. [View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026 ### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research [Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Publication](https://doi.org/10.1038/s41587-026-03099-z) CyteFinder Nature Biotechnology 2026 ### mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression [View Publication](https://doi.org/10.1038/s41587-026-03099-z) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618831/) CyteFinder Cancer Immunology Research 2026 ### Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618831/) [Publication](https://doi.org/10.1097/pai.0000000000001311) CyteFinder Applied Immunohistochemistry & Molecular Morphology 2026 ### Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score [View Publication](https://doi.org/10.1097/pai.0000000000001311) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026 ### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026 ### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma [View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026 ### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.1158/1078-0432.CCR-25-0244) CyteFinder Clinical Cancer Research 2025 ### Pre-clinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-wildtype Glioblastoma [View Publication](https://doi.org/10.1158/1078-0432.CCR-25-0244) [Publication](https://doi.org/10.3390/cancers17162717) CyteFinder Cancers 2025 ### Comprehensive Longitudinal Linear Mixed Modelling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis [View Publication](https://doi.org/10.3390/cancers17162717)